Arimori M, Ikeuchi T
Jpn J Antibiot. 1985 Sep;38(9):2612-6.
The human immunoglobulin (SM-4300), which was developed by Travenol Laboratories, Inc. U.S.A., was used with antibiotics on 12 cases of severe surgical infectious disease. The method of administration and the evaluation of clinical effect of gammaglobulin (SM-4300) were made based upon the criteria of the SM-4300 study group. The clinical evaluation of the effect was classified in 5 grades; excellent, good, fair, poor and unknown. Three types of administration dose schedules were employed. Severe surgical infections were 3 cases of postoperative pneumonia, 3 cases of sepsis with pneumonia, 3 cases of peritonitis, 1 case of cholangitis, 1 case of sepsis with perinephritis and 1 case of subphrenic abscess. Bacterial and immunological examination were also performed before and after the administration of SM-4300. Evaluable cases were 10 cases out of 12 cases. Clinical effects of the administration of SM-4300 were evaluated as excellent in 1 case, good in 3, fair in 2 and poor in 4.
由美国特拉文诺尔实验室公司研制的人免疫球蛋白(SM - 4300),与抗生素一起用于12例严重外科感染性疾病患者。根据SM - 4300研究组的标准进行γ球蛋白(SM - 4300)的给药方法及临床效果评估。临床效果评估分为5个等级:优、良、中、差及未知。采用了三种给药剂量方案。严重外科感染包括3例术后肺炎、3例伴有肺炎的败血症、3例腹膜炎、1例胆管炎、1例伴有肾周炎的败血症和1例膈下脓肿。在给予SM - 4300前后还进行了细菌学和免疫学检查。12例患者中有10例为可评估病例。给予SM - 4300后的临床效果评估为:优1例、良3例、中2例、差4例。